<DOC>
	<DOCNO>NCT02192554</DOCNO>
	<brief_summary>To follow-up safety subject previously treat double-blind trial brexpiprazole .</brief_summary>
	<brief_title>Safety Follow-up Study Subjects With Agitation Associated With Dementia Alzheimer 's Type Who Previously Participated Double-blind Trial Brexpiprazole Placebo</brief_title>
	<detailed_description>Behavioral symptom , agitation , core feature subject Alzheimer 's disease relate dementia , develop majority dementia subject . The presence agitation subject Alzheimer 's disease place significant burden subject caregiver also healthcare system . This trial design assess ongoing safety subject agitation associate dementia Alzheimer 's type complete 12-week double-blind trial brexpiprazole placebo ; drug placebo discontinue prior subject enrol safety follow-up trial . The trial consist continuous 2 month observation period . The trial population include male female subject diagnosis probable Alzheimer 's disease .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>The investigator must assess capacity subject provide inform consent prior enrollment throughout trial . Male female subject complete 12week doubleblind treatment period 30day safety followup visit previous brexpiprazole trial . Subject identify caregiver usually assign care subject regular basis , sufficient contact describe subject 's symptom , direct observation subject 's behavior . Subject able comply protocol requirement . Exclusion Criterion : Subjects , opinion investigator , medical monitor , sponsor participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>OPC-34712</keyword>
	<keyword>brexpiprazole</keyword>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Cognitive Disorders</keyword>
	<keyword>Memory</keyword>
	<keyword>Agitation</keyword>
</DOC>